To cross these obstacles, researchers have investigated the BTZ resistance-reducing effects of various drug combinations and their synergistic anti-MM effects, such as daratumumab (anti-CD38 antibody), BTZ, and dexamethasone (CASTOR trial), TAK-243 (novel and specific UAE inhibitor) and BTZ, decitabine (epigenetic modulator) and BTZ [54,55,56]. This evidence concerns the gene CASC3 and Miyoshi myopathy.